dPCR Mutational Analyses in Cell-Free DNA: A Comparison with Tissues

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Digital PCR (dPCR) is effective for analyzing low-abundance fragmented DNA in blood.
• Liquid biopsies, including plasma cell-free DNA (cfDNA), offer a minimally invasive approach for cancer detection.
• Accurate mutation profiling is crucial for personalized cancer treatment strategies.

Purpose of the Study:

• To comparatively analyze mutations in tumor tissue DNA and plasma cfDNA using dPCR.
• To evaluate the efficacy of dPCR in detecting low-abundance mutations from limited metastatic tissue samples.
• To establish a reliable method for identifying shared mutations between primary tumors and circulating cfDNA.

Main Methods:

• Laser microdissection was employed to isolate tumor cells from small metastatic tissue samples.
• cfDNA was extracted from 500 μL of plasma for mutation analysis.
• A dPCR assay utilizing specific primers and fluorescent probes was developed to detect target gene mutations.

Main Results:

• The dPCR method successfully detected and characterized mutations in both tumor tissue DNA and plasma cfDNA.
• Analysis identified specific mutations present in tumor tissue that were also detectable in plasma cfDNA.
• The study demonstrated the capability of dPCR to identify a limited number of shared mutations.

Conclusions:

• dPCR is a sensitive method for comparative mutation analysis between tumor tissue and cfDNA.
• This approach allows for the identification of key mutations from minimally invasive liquid biopsies.
• The findings support the use of dPCR in cancer mutation profiling and monitoring.